创新驱动发展战略成效显著 华森制药上半年营收利润双增

Core Insights - The company reported a revenue of 442 million yuan for the first half of 2025, representing a year-on-year growth of 5.76% [1] - The net profit attributable to shareholders reached 53.95 million yuan, up 14.27% year-on-year, with a basic earnings per share of 0.13 yuan, also reflecting a growth of 14.24% [1] Financial Performance - Revenue growth was supported by a 29.45% increase in the chemical generic drug segment, which performed well in the market [1] - The five core traditional Chinese medicine products maintained stable revenue growth of 3.52% year-on-year, with significant sales growth in unique products like Pain and Diarrhea Ning Granules and Liuwei Anshen Capsules [1] Innovation and R&D - The company invested 40.50 million yuan in R&D, a 29.33% increase, accounting for over 9% of total revenue [1] - R&D expenses reached 37.04 million yuan, up 43.33% year-on-year, indicating a strong commitment to innovation [1] - The company is advancing seven innovative drug pipelines, focusing on oncology and autoimmune inflammatory diseases, with ORIC-1940 being a leading candidate for a first-in-class innovative drug in China [2] Shareholder Returns - The company announced a mid-term profit distribution plan, proposing a cash dividend of 0.35 yuan per 10 shares, totaling 14.62 million yuan, reflecting its commitment to shareholder returns [2]